SEATTLE--(BUSINESS WIRE)--May 23, 2006--Accium BioSciences, Inc., (Accium) the first fully-commercial Accelerator Mass Spectrometry (AMS) analytical facility in the U.S., and Quintiles Transnational Corp., the world’s leading pharmaceutical services company, today announced the establishment of a partnership to offer turnkey Exploratory-IND, Microdosing and Information-Rich(TM) Phase I clinical trials services to biopharmaceutical researchers. Accium’s Accelerator Mass Spectrometer-based study design expertise and core bioanalytical capabilities combined with the clinical development and regulatory experience and expertise of Quintiles delivers a seamless solution to the critical decision process in early drug development.
